Airsonett

Airsonett is a commercial-stage medical device company offering a unique, clinically validated environmental control therapy for allergic diseases. Its core technology, TLA, is a CE-marked and FDA 510(k)-cleared Class I device that provides a zone of ultra-clean air during sleep, allowing the airways and immune system to recuperate. The treatment is recommended by several European health bodies and health economics studies position it as a cost-effective alternative or adjunct to pharmacological treatments. The company operates primarily in Sweden and the UK, with a business model based on device sales and rentals.

Patented Temperature-controlled Laminar Airflow (TLA) technology that creates a stable canopy of 99.5% allergen-free air over a sleeping patient.

Airsonett competes with the broad standard of care for allergic asthma and eczema, primarily pharmaceutical (inhaled corticosteroids, biologics, topical creams). It also competes with other environmental control products like whole-room HEPA air purifiers and allergen-barrier bedding. Its unique value proposition is the targeted, personal laminar airflow zone, which is clinically differentiated from general air filtration.